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Flavin-containing monooxygenase (FMO), like cytochrome P450 (CYP), is a monooxygenase that uses the reducing equivalents 
of NADPH to reduce one atom of molecular oxygen to water, while the other atom is used to oxidize the substrate. Recently, it 
was shown that some CYP isoforms have been subject to positive selection. However, it is unknown whether the highly conserved 
phase I detoxification enzyme, FMO, has undergone similar positive Darwinian selection. We used maximum-likelihood models 
of codon substitution, evolutionary fingerprinting, and cross species comparison to investigate the occurrence of adaptive evolu-
tion in FMO sequences. We used recent genomic data from a range of species, including vertebrates and invertebrates. We present 
the evidence for the occurrence of adaptive evolution in mammalian FMO 3, 4, 5, and fugu FMOs but not in mammalian FMO 1, 
FMO 2, frog FMOs, other fish FMOs and invertebrate FMOs. The sites under adaptive evolution were significantly associated 
with the insertion domain in mammalian FMO 5. We identified specific amino acid sites in FMOs 3–5 that are likely targets for 
selection based on the patterns of parallel amino acid change. The most likely role of adaptive evolution is the repair of mutations 
that permitted optimal NADP+ binding and improved catalytic efficiency. The occurrence of positive selection during the evolu-
tion of phase I detoxification enzymes such as FMOs 3–5 and fugu FMO suggests the occurrence of both high selection pressure 
acting on species within their unique habitats and significant changes in intensity and direction (forms of xenobiotics and drugs) 
resulting from changes in microhabitat and food. 
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Flavin-containing monooxygenases (FMOs, E.C. 1.14.13.8) 
oxygenate the nucleophilic O, N, S and Se atoms of a wide 
range of substrates, including amines, amides, thiols and 
sulfides. FMO, like cytochrome P450 (CYP), is a monoo- 
xygenase that uses the reducing equivalents of NADPH to 
reduce one atom of molecular oxygen to water, while the 
other atom is used to oxidize the substrate. Similarly, FMO 
and CYP also share similar tissue and cellular distributions, 
molecular weights, substrate specificities, and both exist as 
multiple enzymes that are under developmental control. The 
human FMO functional gene family is much smaller 
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(5 families each with a single member) than the CYP family. 
Furthermore, FMO does not require a reductase to transfer 
electrons from NADPH and the catalytic cycle of the two 
monooxygenases also differs significantly. The FMOs asso-
ciated with liver microsomes are divided into 3 classes: 
FMOs, N-hydroxylating monooxygenases, and Baeyer-Vil-
ligar monooxygenases (BVMOs). BVMO and FMO may be 
distinguished by their signature sequences FXGXXXHXX- 
XW(P/D) and FXGXXXHXXX(Y/F), respectively. In gen-
eral, CYP is the primary contributor to oxidative xenobiotic 
metabolism. However, an increasing number of drugs and 
xenobiotic substances are known to be metabolized by FMOs 
[1,2]. FMO and CYP have overlapping substrate specificities, 
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but often yield distinct metabolites with potentially signifi-
cant toxicological/pharmacological consequences. 
An increasing number of researchers study gene function 
and regulation using population genetics and phylogeno- 
mics techniques. This approach is aided by the rapidly ex-
panding effort towards genome sequencing and genotyping. 
The evolution of a gene’s sequence among human popula-
tions or species reflects, in part, adaptations to changing 
physiology or environment. Recently, Qiu et al. [3] investi-
gated the evolution of the CYP3 genomic loci using ge-
nomic sequences from 16 species, and found 2 recent epi-
sodes of particularly strong positive selection acting on 
primate CYP3A4 and 3A7 protein-coding sequences. 
Zawaira et al. [4] used maximum-likelihood models of 
codon substitution to investigate the role of adaptive evolu-
tion in the evolution of CYP sequences, and found evidence 
for the occurrence of adaptive evolution in the evolution of 
rat CYP2C, rabbit CYP2C, rat CYP2D, human CYP3A, and 
rabbit CYP4A. In addition, Chen et al. [5] conducted a 
comprehensive study of the nucleotide diversity and haplo-
type structure of the CYP3A locus and concluded that 
CYP3A4 and 3A7 had recently undergone, or were under-
going, a selective sweep in all 3 populations under study. 
However, CYP3A43 and 3A5 were undergoing a selective 
sweep in non-Africans and Caucasians, respectively.  
In contrast to the depth of information on the CYP fam- 
ily, little is known about the evolution of FMOs. Allerston 
et al. [6] analyzed the genetic diversity within FMO 3 and 
found an excess of intermediate-frequency SNPs and hap-
lotypes, a ragged pairwise mismatch distribution, and an 
excess of replacement polymorphisms, providing evidence 
that FMO 3 has been the subject of balancing selection. Hao 
et al. [7] reconstructed a phylogenetic tree for the FMO 
family and characterized the long-term evolution and func-
tional divergence followed by members of this family. The 
authors noted that there is extensive silent divergence at the 
nucleotide level suggesting that this family has been subject 
to strong purifying selection at the protein level. However, 
recently published genomic data from a range of species, 
including vertebrates and invertebrates, have not yet been 
fully evaluated with respect to determining the evolution of 
FMOs. The whole genome sequencing of a rapidly increas-
ing number of species facilitates studies of the evolution of 
gene families using a comparative genomic approach. Given 
the similarities between FMO and CYP, we hypothesize 
that FMO is also subject to positive Darwinian selection. 
We test this hypothesis using a maximum-likelihood ap-
proach and cross species sequence comparison.  
1  Methods 
1.1  Orthologous sequences 
We retrieved 106 sequences from Ensembl (http://www. 
ensembl.org) (Dataset S1 and Table 1).  
1.2  Paralogous sequences 
We used 46 sequences, including 9 Strongylocentrotus 
purpuratus (purple sea urchin) sequences (Dataset S1 and 
Table S1).  
The protein database predicted from the S. purpuratus 
genome (release 2.1) [8] was searched using hidden Markov 
models (HMMs) of FMOs constructed with Hmmer 2.3 [9]. 
The HMM was constructed with FMOs from humans, mice, 
rats, and fish. Both global and local multidomain HMMs 
were constructed and used to search the predicted protein 
database. Predicted proteins were aligned with known 
FMOs using Clustal W2 [10]. Examination of the S. purpu-
ratus genome assembly using Blast searching confirmed the 
FMO protein sequence predictions. Genome sequences 
were obtained from GenBank, Ensembl, and the Joint Ge-
nome Institute. Some preliminary gene predictions were 
performed using Genewise [11] and Genscan [12]. 
1.3  Sequence alignment and phylogeny reconstruction 
DNA sequence and codon alignments were performed with 
RevTrans [13] (http://www.cbs.dtu.dk/services/RevTrans/) 
and Clustal W2. For amino acid sequences, we used the 
neighbor-joining (NJ) method [14] to reconstruct the phy-
logenetic tree with MEGA4 [15]. The best model, JTT + G,  
Table 1  Likelihood ratio statistics and AICc scores for tests of positive selection of orthologous FMO sequencesa) 
M8 vs. M8a (df = 1) MEC vs. M8a M8 vs. M7 (df=2) Gene family 
(no. of genes) Log-likelihood P Log-likelihood AICc Log-likelihood P 
FMO 1(24) –12840.2/–12840.2 Not significant –12741.7/–12840.2 25493.4/25688.4 –12840.2/ –12846.1 0.002739 
FMO 2(23) –12555.8/–12579.4 0.000 –12515.5/–12579.4 25041.0/25166.8 –12555.8/ –12586.7 0.000 
FMO 3(18) –10488.1/–10491.4 0.010198 –10417.9/–10491.4 20845.8/20990.8 –10488.1/–10500.5 0.000004 
FMO 4(19) –12228.4/–12241.4 0.000 –12115/–12241.4 24240.0/24490.8 –12228.4/–12255.6 0.000 
FMO 5(22) –13188.5/–13206.1 0.000 –13022.5/–13206.1 26055.0/26420.2 –13188.5/–13224.1 0.000 
a) –2ΔlnL = 2(lnLalternative hypothesis–lnLnull hypothesis), χ2 distribution. AICc=–2 log L+2pN/(N–P–1); L, likelihood; P, no. of free parameters; N, the sequence 
length. The smaller the AICc value, the better the model explains the data. For FMOs 1–5, the likelihood ratio test (LRT) between the models MEC and M8a 
indicates a significance level of: AICc score of MEC is lower than M8a, significance test passed. Sites under positive selection identified by M8 and MEC 
are listed in Table 2. The occurrence of positive selection in FMO 2 was not supported by the evolutionary fingerprint analysis (Figure 2) and parallel amino 
acid substitution (Table S3). 
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Table 2  Positively selected amino acid sites in orthologous mammalian FMOsa) 
 FMO 1 FMO 2 FMO 3 FMO 4 FMO 5 
SLAC 243L None 92I 116H 236V 350I 311V 






92I 111S 116H 236V 318I  
350I 360L 378A 459M  
506Q 512F 527V 
121E 218T 244A 278K 296I 311V 
88V 232A 240L 253A  
255K 263Q 343V  






35N 92I 93A 109F 114N 121T  
164N 181V 235L 236V 318I  
332S 360L 417R 432V 459M 
500R 503G 504R 512F 527V 
89D 121E 221L 226D 231Y 235V 240C  
244A 256Q 259K 281F 311V 323V 354Q  
474M 501I 517A 537L 543K 545Q 556b)  
553V 554S 555L 556W 558G 
132S 182G 232A 242H 248C 250Q
253A 255K 256Y 263Q 297L 410S 
412A 471I 504V 506R 511T 513T 
M8 131H 240R 360L 504R 
89D 221L 226D 231Y 235V 259K 281F  
323V 354Q 537L 545Q 554S 
561Q(platypus)c) 
182G 232A 235L 236F 241T 242H 
244I 245W 248C 250Q 252L 253A 






180D 252V 441L 
449F 450C  
506G(platypus)c) 
35N 74F 93A 135K 235L  
360L 417R 432V 459M  
498Q 504R 
85E 89D 121E 136N 154H 221L 226D  
231Y 235V 259K 279A 281F 323V 354Q  
374K 474M 501I 537L 540V 542D  
543K 545Q 555V(platypus)c) 553V 554S  
555L 556W 560Q(platypus)c)  
561Q(platypus)c) 
106R 182G 232A 235L 241T 242H 
244I 245W 248C 250Q 252L 253A 
255K 256Y 260K 297L 492D  
510M 513T 
a) Sites under positive selection detected by various models are listed according to the human sequence numbering. Positively selected sites in FMOs 3–5 
detected by M8 model are in bold type, some of which are also detected by other methods. b) Alignment position; no amino acid for human FMOs aligned 
on this position. c) No amino acid for human FMOs aligned on this position (according to the platypus sequence numbering); the amino acid for platypus 
FMOs at this position is shown. 
 
was identified using ProtTest [16]. To determine whether 
the outcome was dependent on this choice, we conducted a 
phylogenetic inference analysis by reconstructing a Bayes-
ian tree (MrBayes 3.1.2) [17] with 4 Markov chain Monte 
Carlo chains run for 1×106 generations. For the nucleotide 
sequences, we used a Bayesian analysis and the maximum 
likelihood (ML) method (GARLI) [18] to infer the phy-
logenetic trees. The best model, GTR + I + G, was selected 
using ModelTest 3.8. Bayesian probabilities were obtained 
under this model using a Markov chain Monte Carlo simu-
lation (MCMC: 4 chains, each runs for 4×106 generations). 
We used random trees as the starting point and sampling 
every 500th generation. To test the reliability of the ob-
tained topologies, we calculated bootstrap probability (BP) 
and posterior probability (PP) values for each internal 
branch, assuming that BP≥80% and PP≥95% were statisti-
cally significant. S. pombe FMO [19] and the FMO from 
Saccharomyces cerevisiae [20] were assigned as outgroups 
in the reconstructions. 
1.4  Detection of positively selected sites and evolution-
ary fingerprint analyses 
We tested for evidence of positive selection by comparing 
the nonsynonymous substitution rate (dN) to the synony-
mous substitution rate (dS). If a gene is evolving neutrally, 
ω = dN/dS is expected to equal 1, whereas ω>1 is considered 
strong evidence that a gene has experienced positive selec-
tion. We used several ML approaches to test for evidence of 
positive selection on FMOs. The first approach, developed 
by Yang et al. [21] (referred to as Yang models), involves 
comparisons of a neutral codon substitution model with ω 
constrained to be ≤1 to a selection model where a class of 
sites has ω>1. Because neutral models are nested within the 
corresponding selection models, a likelihood ratio test 
(LRT) can be used to compare the two. The test statistic 
–2ΔlnL (ΔlnL = the difference in log likelihoods of the 2 
models) follows the χ2 distribution with degrees of freedom 
(df) equal to the difference in number of parameters be-
tween models. In the specific models implemented, ω varies 
between codons as a beta distribution (neutral: M7, M8a; 
selection: M8). We implemented models M7, M8a, and M8 
with the codeml program in PAML4 [22]. Because Yang 
models are based on theoretical assumptions and ignore the 
empirical observation that distinct amino acids differ in 
their replacement rates, we also implemented the MEC 
(Mechanistic Empirical Combination) model [23]. This 
takes into account not only the transition-transversion bias 
and the nonsynonymous/synonymous ratio, but also the 
different amino acid replacement probabilities as specified 
in empirical amino acid matrices. Because the LRT is ap-
plicable only when two models are nested and is therefore 
not suitable for comparing MEC and M8a models, we used 
the second-order AIC (AICc) for comparisons [23]. Those 
sites that are most likely to be in the positive selection class 
(ω>1) are identified as likely targets of selection. 
Although the Yang models allow for variation in the 
nonsynonymous substitution rate, the synonymous rate is 
fixed across the sequence. A number of methods have been 
proposed for detecting positive selection that allow for 
variation in the synonymous rate (e.g., fixed effects meth-
ods and random effects methods). The fixed effect likeli-
hood (FEL) method [24] estimates ω on a site-by-site basis, 
uses ML estimation, and treats shared parameters (branch 
lengths, tree topology, and nucleotide substitution rates) as 
fixed. The random effects likelihood (REL) method is simi-
lar to the Yang model M3. However, both nonsynonymous 
and synonymous rates vary as gamma distributions with 3 
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rate classes [24]. We implemented the REL, FEL, and SLAC 
methods using the web interface DATAMONKEY [25]. 
Over time, natural selection molds every gene into a 
unique mosaic of sites that evolve rapidly or resist change, 
an “evolutionary fingerprint” of the gene. Pond et al. [26] 
developed a novel model for coding sequence evolution that 
uses a general bivariate discrete parameterization of the 
evolutionary rates. This approach provides a better fit to the 
data using a smaller number of parameters than existing 
models. We used the probability distributions generated 
using this method to represent the evolutionary fingerprints 
of the FMOs under consideration. 
1.5  Parallel amino acid substitutions 
Parallel and convergent evolution refer to independent ac-
quisitions of the same character state on more than one oc-
casion during evolution. The distinction between parallel-
ism and convergence is that the former refers to the situa-
tion in which the ancestral states were identical among in-
dependent lineages, whereas the latter requires different 
ancestral states [27]. To identify parallel amino acid substi-
tutions, we performed ML reconstructions of ancestral se-
quences and individual mutation events using PAML4 
(baseml and pamp). The marginal reconstruction approach 
[28] compares the probabilities of different character as-
signments to an interior node at a site and selects the charac-
ter that has the highest PP. We then calculated the number of 
independent changes, Grantham’s distance [29] between the 
starting and ending amino acid, the universal evolutionary 
index (EI) [30], and the possible alternative amino acid sub-
stitutions for the identified parallel amino acid substitutions. 
1.6  Statistical significance of the overlap between sites 
under adaptive evolution and defined insertion domain 
S. pombe FMO (447 aa) consists of two structural domains 
[19]. Residues 176–291 form a small structural domain, i.e., 
the insertion domain (ID), with the remainder of the poly-
peptide chain forming a larger single domain. The prokary-
otic FMO from Methylophaga sp. strain SK1 is made up of 
2 distinct domains [31], a larger FAD-binding domain 
(residues 1–169 and 281–461) and a smaller NADP-binding 
domain (residues 170–280, corresponding to the ID of the 
yeast FMO). The positions of the ID in mammalian FMOs 
were assigned according to the sequence alignment with 
yeast and bacterial FMOs (Figure 1). In addition, we de-
fined the active sites (ASs) of mammalian FMOs by ex-
tending the yeast and bacterial FMO ASs by 3 amino acid 
residues on both sides (Figures 1 and S1). 
We constructed a model for analyzing the statistical sig-
nificance of the overlap between the sites under adaptive 
evolution and the ID as follows. Let X be the total number 
of sites (for analysis of a given gene or set of genes as listed 
in the first column of Tables 1 and S1) predicted to be under 
adaptive evolution that lie in the ID. We used the binomial 
distribution to model X. To test the statistical significance of 
the overlap between the model-predicted sites and the ID, 
we tested the null hypothesis that the probability of a pre-
dicted site lying in the ID (which we refer to as P) is half, 
versus the alternative hypothesis that P is greater than half, 
that is:  
H0:P =0.5 vs. H1:P>0.5. 
If the null hypothesis is accepted, the observed propor-
tions support the conclusion that the model-predicted sites 
are equally likely to lie inside or outside the ID, implying a 
weak association between the predicted sites and the ID. In 
contrast, rejection of the null hypothesis supports the con-
clusion that there is an association between the predicted 
sites and the ID, i.e., the observed overlap between sites 
under adaptive evolution and the ID is greater than that ex-
pected from chance alone (where the adaptive evolution 
sites are equally likely to occur inside or outside the ID). If 
n is the number of predicted sites in a given analysis then 
under the H0 the probability that X takes the value r [de-
noted to by P(X=r)] is given by the binomial distribution as 
follows:  
1 1 1( )
2 2 2
! 1 .
( )!( )! 2
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We performed a one-tailed test with a significance level 
of 10%. This involved finding an integer (a) such that 
P(X≥a) < 0.1. For a given study, the value of a defines the 
rejection/acceptance criteria as follows: if X<a, then the 
integer a does not lie in the critical region and the null hy-
pothesis is accepted, otherwise it is rejected and the alterna-
tive hypothesis accepted. 
2  Results  
2.1  Maximum-likelihood analysis of orthologous and 
paralogous FMO sequences 
The positively selected sites of the orthologous and paralo-
gous sequences obtained from the maximum-likelihood 
inferences are shown in Tables 1, 2 and S1, respectively. 
We identified positively selected sites in the FMOs 3, 4, and 
5 orthologs and in the fugu FMO paralogs. Based on the 
evolutionary fingerprint analysis, both FMOs 4 and 5 have 5 
evolutionary rate classes, fugu FMOs have 4 rate classes, 
and FMO 3 has 3 rate classes (Figure 2). The presence of 
one rate class with ω (β/α) >1 in these 4 groups suggests the 
occurrence of positive selection. The SLAC, FEL, REL, M8 
and MEC models suggested that one or several FMO 1 sites 
may have been subject to positive selection. However, the 
evolutionary fingerprint analysis did not yield evidence of 
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Figure 1  The insertion domain (ID) and the positively selected (PS) FMO sites. Alignment of the sequences of Methylophaga FMO (meFMO), human 
FMO 3 (FMO3), FMO 4, FMO 5, fugu FMO (ENSTRUT00000042461), and S. pombe FMO (spFMO) is shown. Sequence identities to human FMO 3 are 
31% for meFMO, 27% for spFMO, 42% for fugu FMO, 52% for human FMO 4, and 52% for human FMO 5. The ID was defined by profile alignment using 
ClustalW2 and its boundary is shown with “start” and “end”, corresponding to the alignment positions 189 and 390, respectively. We defined active sites 
(AS) by extending the Methylophaga FMO active sites by three amino acids on both sides. ASs 3 (alignment positions 188–194) and 4 (alignment positions 
236–246) are indicated with “^” and black “*”, respectively; ASs 1, 2, 5, and 6 were not within the ID region and are shown in Figure S1. “+”, positively 
selected sites detected by the M8 model and lying within the ID region. The alignment positions of the PS sites are as follows: 269, 274, 280, 284, 308, 335, 
and 382 of FMO 4; 226, 280, 283, 284, 289, 290, 292, 293, 296, 298, 300, 301, 303, and 308 of FMO 5; 290 of fugu FMO. “------” and “===” represent the 
fingerprint sequences of FMOs that are similar to the BVMO-identifying sequence motif and the second Rossmann fold for NADPH binding, respectively. 
Common SNPs located within ID region are labeled with “#”, “%”, and “@” for human FMOs 3, 4, and 5, respectively. “&” indicates FMO 3 residues that 
are mutated in patients affected by TMAU. 
positive selection for FMO 1 (Figure 2). Similarly, none of 
the rate classes supported the occurrence of positive selec-
tion in FMO 2 (Figure 2), although the FEL, M8 and MEC 
models provided support for positive selection at one or 
several FMO 2 sites. The discrepancies between the differ-
ent models are a function of their underlying mathematical 
and statistical relationships. To reduce the potential for bias, 
we used a range of methods to predict the presence of posi-
tive selection. All Europeans and Asians tested were ho-
mozygous for a non-functional FMO 2 variant (FMO2*2A) 
that contains a premature stop codon caused by a single 
nucleotide change in exon 9 (g. 23238C>T) [32]. This is 
exactly as would be expected under the birth-and-death 
evolution model [33] and implies nonfunctionalization [34] 
after gene duplication. To be stringent, we do not consider 
FMOs 1 and 2 to be under positive selection. In addition, 
we found no evidence for positive selection at sites in the 
sea urchin, medaka, tetraodon, and other non-mammalian 
data sets, except fugu FMOs (Table S1). 
2.2  Parallel amino acid substitutions 
The pattern of amino acid change based on ML ancestral 
sequence reconstruction provides further evidence that 
FMOs 3–5 evolved under positive selection. Twenty seven 
amino acid sites in FMO 3, 34 sites in FMO 4, and 32 sites 
in FMO 5 changed independently to the same amino acid in 
2 or more mammalian species (Table S3). For example, site 
360 in FMO 3 changed from the polar residue glutamine (Q) 
to the nonpolar leucine (L) in tarsier and the lesser hedgehog 
tenrec (Figure 3(a)). In FMO 4, site 235 changed from the 
nonpolar valine (V) to the negatively charged aspartate (D)  
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Figure 2  Phylogenetic relationships among FMO proteins and the evolutionary fingerprint of each FMO lineage. The reconstruction was carried out using 
the JTT + G model. The tree/branch style is shown as a circle. The tree is drawn to scale, with branch lengths in the same units as those of the evolutionary 
distances used to infer the phylogenetic tree. The evolutionary distances are in the units of the number of amino acid substitutions per site. The concept of an 
evolutionary fingerprint is formulated based on the probability distribution of site-to-site of synonymous (α) and nonsynonymous (β) substitution rates in an 
alignment [26]. Methods that exploit the ω = β/α ratio as an indicator of positive or negative selection have become a mainstay of modern evolutionary 
analyses. An accurate estimate of the strength and extent of selective forces acting on a gene, represented by a distribution of α and β, is undoubtedly more 
informative than a simple binary test for any kind of positive selection. The panel beside each FMO lineage shows the approximate sampling distributions, 
which are drawn on the log scale that is consistent between all 10 data sets, with α on the x axis and β on the y axis, and the diagonal line corresponding to 
values α = β: A proxy for neutral evolution. The color intensity reflects the density assigned to a particular square of the rate distribution. The ellipses are 
centered on the approximate sampling means of the corresponding rate estimates, and each axis is drawn as 1.96× the sampling standard deviation for α 
(horizontal) or β (vertical) rates. 
in bushbabies and dolphins (Figure 3(b)). This change was 
classified as radical based on Grantham’s distance, which 
takes into account amino acid size, hydrophobicity, charge, 
and polarity. This classification was supported by the uni-
versal evolutionary index (EI, Table S3). Changes from a 
noncharged to a charged residue were found in FMOs 4 and 
5. Changes at 2 sites in FMO 3, 6 sites in FMO 4, and 2 
sites in FMO 5 were not conservative or moderately con-
servative, as defined by changes in charge or by Grantham’s 
distance. There was no significant difference in the distribu-
tion of the four types of amino acid change among FMOs 
3–5 (chi square test, χ2=3.86, P=0.695). Such nonconserva-
tive changes occur much less frequently than is expected 
under neutrality [35]. Thus, the nonconservative changes 
observed are more likely to have consequences for enzyme 
structure and/or function. Parallel evolution at the amino  
acid sequence level can be interpreted as evidence of adap-
tive evolution [27]. Thus, sites that have changed in parallel 
are likely targets of selection, in addition to those sites iden-
tified using the ML approach. Our results also suggest that 
the number of available pathways of adaptive evolution may 
be constrained. 
2.3  Assignment of predicted sites under adaptive evo-
lution to the map of the insertion domain and active sites 
The predicted sites under adaptive evolution (listed in Ta-
bles 2 and S1) were projected onto the map of the ID and 
AS (i.e., onto the structure of yeast and bacterial FMOs) 
[31] using the profile alignment strategy. The projections 
shown in Figure 1 were carried out for FMOs 3–5 and fugu 
FMO where adaptive evolution was observed (Figure 2).  
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2.4  Statistical significance of the overlap between sites  
under adaptive evolution and the insertion domain of  
the FMOs 
We used the binomial distribution to model the total number 
of sites predicted to be under adaptive evolution that lie 
either inside (Figure 1) or outside the ID. The statistical 
analysis is summarized in Table S2. A significant number 
(14 of 16) of positively selected sites in FMO 5 were lo-
cated in the ID. Similarly, a significant number (4 of 4) 
positively selected sites in the fugu FMOs detected by MEC 
model were located in the ID. These sites may have con-
tributed to the fugu’s adaptation to specific aquatic envi-
ronments. None of the positively selected sites in FMOs 3 
and 4 were located in ASs 1–6. In addition, only one posi-
tively selected site (465L) in FMO 5 was in AS-6 (Figure 
S1). In contrast, Zawaira et al. [4] found a significant asso-
ciation between sites under adaptive evolution and Gotoh’s 
substrate recognition sites (SRSs) in rat and rabbit CYP2C, 
human CYP3A, and rat CYP2D. Furthermore, 2 of 3 posi-
tively selected sites in the primate CYP3A were in SRS-6 
[3]. The method for assessing the statistical significance of 
the overlap between the sites under adaptive evolution and 
the ID assumes that all positions in the non-ID region are 
functionally relevant, either for substrate specificity, bind-
ing NADP+, or enzyme kinetics. This assumption should be 
supported or modified based on experimental evidence. Our 
map of the ID and ASs is complete given current data, but 
should be updated when information regarding sub-
strate-binding sites encoded in FMO-substrate complexes 
and mutagenesis become available.  
3  Discussion and conclusions 
FMOs play an important role in mediating interactions be-
tween organisms and their chemical environment due to 
their involvement in the metabolism of xenobiotics and en-
dobiotics. Thus, they are likely targets for natural selection. 
Previously, we suggested that FMOs are subject to strong 
purifying selection [7]. Allerston et al. [6] provided popula-
tion genetic evidence that human FMO 3 has been subject to 
balancing selection, but not positive selection. To further 
our understanding of the evolutionary history of the FMO 
loci, we analyzed mammalian and non-mammalian DNA and 
protein sequence variation within a phylogenetic framework. 
For the first time, we unambiguously identified a number of 
positively selected sites in FMOs 3–5 and showed that the 
loci have been subject to adaptive evolution. 
FMOs belong to the flavoenzyme class of single compo-
nent flavoprotein monooxygenases. They use equivalents 
from NADPH to reduce the FAD cofactor which, in turn, 
becomes capable of reacting with molecular oxygen to yield 
the C4a-hydroperoxy FAD intermediate [31]. A defining 
characteristic of this reaction is that the presence of NADP+ 
is essential for intermediate stabilization. Furthermore, 
NADP+ remains consistently bound to the insertion domain 
of the enzyme throughout the catalytic cycle, being the last 
product to be released. Interestingly, we observed a signifi-
cant overlap between the FMO 5 sites under adaptive evolu-
tion (PAML-predicted) and the insertion domain. The most 
likely role of adaptive evolution is to repair the mutations 
that permitted optimal NADP+ binding and improved  
 
Figure 3  Mapped codon substitutions for site 360 of FMO 3 (a) and site 235 of FMO 4 (b). Substitutions by branch are shown. The scale (substitutions per 
site) for each gene is indicated in each tree. Tree branches are color coded by the type of substitutions as follows: both synonymous and non-synonymous
(yellow), only synonymous (blue), only non-synonymous (red). (a) Site 360 in FMO 3 changed from the polar residue glutamine (Q) to the nonpolar leucine 
(L) in tarsier and lesser hedgehog tenrec; (b) site 235 in FMO 4 changed from the nonpolar valine (V) to the negatively charged aspartate (D) in bushbabies 
and dolphins. 
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catalytic efficiency toward the expanding substrate reper-
toire during long-term evolution of FMO 5. Compared to 
FMOs 1–4, FMO 5 is ancient in origin [7]. FMO 5 is the 
most prominent form of FMO in the fetal liver. FMO 5 and 
FMO 3 transcripts are both prevalent in human adult liver. 
FMO 5 is also the most abundant FMO transcript present in 
the human small intestine and may contribute to intestinal 
first-pass metabolism [36]. FMO 5 does not oxygenate 
typical FMO substrates (i.e., methimazole, ranitidine, or 
cimetidine) [37,38], but has been reported to S-oxygenate 
thioethers with a proximal carboxylic acid, a somewhat 
unique FMO substrate activity [39]. The dietary anticar-
cinogen quercetin enhanced the action of genes involved in 
phases I and II metabolism, including FMO 5 [40]. E7016, 
an inhibitor of poly(ADP-ribose) polymerase, undergoes 
FMO 5-mediated Baeyer-Villiger oxidation in liver micro-
somes [41]. The specificity of FMO 5 toward catalyzing this 
Baeyer-Villiger oxidation was confirmed and may be medi-
ated by the amino acid residues in the ID that are under 
adaptive evolution as these positively selected sites are ad-
jacent to the well-known signature motif FXGXXXHX- 
XX(Y/F) which is very similar to that of the active site of 
the BVMOs. As more specific substrates are discovered, 
FMO 5 may show selective functional activity. Thus, we 
speculate that FMO 5 differentiated at an early stage, fol-
lowing the split from the common ancestor of FMOs 1–4, to 
fulfill a critical role in the liver and intestine. The evolu-
tionary fate of FMO 5 is consistent with the neofunctionali-
zation model that predicts that one of the duplicated genes 
acquires a new function because of positive Darwinian se-
lection. Whether the positively selected sites found in this 
study are related to the distinct monooxygenation profile of 
FMO 5 for a large repertoire of xenobiotic agents requires 
further experimental study. 
Seven out of 13 positively selected FMO 4 sites are lo-
cated in the ID, 5 in the C-terminal region and only 1 in the 
highly conserved N-terminal region. This is reasonable bio-
logically because genetic variability at the FMO 4 locus has 
presumably evolved to detoxify novel types of xenobiotics 
and drugs. FMO 4 is the least studied FMO isoform. The 
loci for FMOs 1–4 diverged from the ancestral FMO locus a 
long time ago and now have different functions and me-
tabolize different substrates [7]. Whereas other FMOs dis-
played a significant, dominant tissue-specific mRNA profile 
(i.e., FMO 1 in kidney, FMO 2 in lung, FMOs 3 and 5 in 
adult liver), FMO 4 mRNA was observed more broadly at 
relatively comparable levels in the liver, kidney, lung, and 
small intestine [36]. Real time quantitative RT-PCR con-
firmed that 20 μmol/L p-NO-ASA (NO-donating aspirin) 
upregulated FMO 4 by 4.5±1.67-fold [42]. Taken together, 
these observations illustrate FMO subfunctionalization 
which, in addition to neofunctionalization and nonfunction-
alization [34] following FMO gene duplication, increases 
the complexity of the evolutionary scenario. 
Although neofunctionalization may not be important for 
the evolution of FMOs 1 (the predominant FMO in the fetal 
liver) and 2 (tend to nonfunctionalization), it is reasonable 
to postulate that, given a constantly changing environment, 
some positively selected sites were involved in the neofunc-
tionalization of FMOs 3–5. Following the relatively recent 
split of FMO 4 and the common ancestor of FMOs 1 and 3 
(Figure 2), these detoxification enzymes are currently in the 
process of specialization. Due to limited knowledge regard-
ing substrate specificity and the lack of information on the 
3-D structures of mammalian FMOs, we are unable to ade-
quately explain why positively selected sites were observed 
in FMOs 3–5, but not in FMOs 1 and 2. 
Mammalian FMO 3 oxygenates a variety of nucleophilic 
primary, secondary, and tertiary amines, as well as sulfur 
and other heteroatom-containing chemicals and drugs [1]. 
Because FMO 3 is not readily induced or inhibited, varia-
tion in the functional activity is derived from genetic vari-
ability arising largely from common SNPs (Figures 1 and 
S1). Conversely, individuals with rare FMO 3 mutations 
that cause defective TMA N-oxygenation suffer from 
trimethylaminuria (TMAU). Allerston et al. [6] found no 
evidence for positive selection when only considering the 
intraspecific FMO 3 sequence variation. Conversely, we 
found two positively selected sites using the M8 model by 
comparing interspecific sequence variation, which suggests 
that adaptive evolution has had a role in the long-term, but 
not short-term, evolution of FMO 3. One of positively se-
lected sites is 360Leu, a polymorphic site. A small number 
of individuals (i.e., 1%) possessed the Pro360-FMO 3 vari-
ant, which is catalytically more efficient than the wild-type 
FMO 3 [43]. P360-FMO 3 oxygenated mercaptoimidazole, 
TMA, and 10-(N,N-dimethylaminopentyl)-2-(trifluorome- 
thyl)phenothiazine approximately 3-, 5-, and 2-fold more 
efficiently, respectively, than wild-type FMO 3. For these 
substrates, the Km values for P360-FMO 3 and the wild-type 
enzyme were similar, but the Vmax values were greater. It is 
possible that being adjacent to the insertion domain, 
P360-FMO3 is able to facilitate desorption of NADP+ or 
dehydration of FAD pseudobase water and, thus, speed up 
the FMO reaction [44]. Another possibility is that 
P360-FMO 3 modifies the structure of FMO 3. It is known 
that substitution of Pro into an enzyme can change protein 
structure. Analogously, the change in amino acid from Q to 
L, or other cases on site 360, may have adjusted the spatial 
relationship and/or modified the affinity between the inser-
tion domain and NADP+, thus optimizing FMO 3 reactions 
with newly encountered substrates in the environment. 
In conclusion, we present the first evidence for the oc-
currence of adaptive evolution in mammalian FMOs 3, 4, 5, 
and fugu FMOs. The adaptive evolution signal was not de-
tected in mammalian FMOs 1, 2, frog FMOs, other fish 
FMOs, and invertebrate FMOs. Our results show distinct 
patterns of evolution for mammalian FMOs 1 and 3, both of 
which have a recent origin. Furthermore, the sites under 
adaptive evolution are significantly associated with the in-
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sertion domain in mammalian FMO 5. Whether the identi-
fied positive selection and the parallel amino acid substitu-
tion alter the product profile in the respective species de-
serves further study. The finding of positive selection dur-
ing the evolution of phase I detoxification enzymes such as 
FMOs 3–5 and fugu FMO is counterintuitive in the light of 
the supposed limited room for change in these molecules. 
Our results support expectations of both high selection 
pressure acting on the various species within their unique 
habitats and significant changes in intensity and direction 
(kinds of xenobiotics and drugs) resulting from changes in 
microhabitat and food. Future studies of enzyme structure, 
substrate specificity, and catalytic mechanism would benefit 
from site-directed mutagenesis based on our current results. 
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